Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Pharmaleads","sponsor":"IACTA Pharmaceuticals","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"IACTA Pharmaceuticals and Pharmaleads to Develop the World's First Epithelial Protective Drug","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"FRANCE","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Ophthalmology","graph2":"IND Enabling"}]

    Find Clinical Drug Pipeline Developments & Deals by Pharmaleads

    Menu

    Pharmaleads

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Pharmaleads

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              IACTA Pharmaceuticals and Pharmaleads to Develop the World's First Epithelial Protective Drug

              Details:

              Under the terms of these agreements, Pharmaleads and Pharmaleads Greater China have granted IACTA an exclusive, worldwide, royalty-bearing license to lead the clinical and commercial development of IC800 (acute) and IC805 and other DENKI drugs from Pharmaleads’ portfolio.

              Lead Product(s): IC 800

              Therapeutic Area: Ophthalmology Product Name: IC 800

              Highest Development Status: IND Enabling Product Type: Undisclosed

              Partner/Sponsor/Collaborator: IACTA Pharmaceuticals

              Deal Size: $100.0 million Upfront Cash: Undisclosed

              Deal Type: Collaboration January 07, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY